Lange Y, Ye J, Chin J
Department of Pathology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA.
J Biol Chem. 1997 Jul 4;272(27):17018-22. doi: 10.1074/jbc.272.27.17018.
Cholesterol released from ingested low density lipoproteins in lysosomes moves both to the plasma membrane and to the endoplasmic reticulum (ER) where it is re-esterified. Whether cholesterol can move directly from lysosomes to ER or first must traverse the plasma membrane has not been established. To examine this question, the endocytic pathway of rat hepatoma cells was loaded at 18 degrees C with low density lipoproteins (LDL) labeled with [3H]cholesteryl linoleate, and the label then was chased at 37 degrees C. The hydrolysis of the accumulated ester proceeded linearly for several hours. Almost all of the released [3H]cholesterol moved to the plasma membrane rapidly and without a discernable lag. In contrast, the re-esterification in the ER of the released [3H]cholesterol showed a characteristic lag of 0.5-1 h. These data are inconsistent with direct cholesterol transfer from lysosomes to ER; rather, they suggest movement through the plasma membrane. Furthermore, we found that progesterone, imipramine and 3-beta-[2-(diethylamino)ethoxy]androst-5-en-17-one (U18666A) strongly inhibited the re-esterification of lysosomal cholesterol in the ER. However, contrary to previous reports, they did not block transfer of [3H]cholesterol from lysosomes to the cell surface. Therefore, the site of action of these agents was not at the lysosomes. We suggest instead that their known ability to block cholesterol movement from the plasma membrane to the ER accounts for the inhibition of lysosomal cholesterol esterification. These findings are consistent with the hypothesis that cholesterol released from lysosomes passes through the plasma membrane on its way to the ER rather than proceeding there directly. As a result, ingested cholesterol is subject to the same homeostatic regulation as the bulk of cell cholesterol, which is located in the plasma membrane.
从溶酶体中摄取的低密度脂蛋白释放出的胆固醇会移动到质膜和内质网(ER),并在那里重新酯化。胆固醇是否能直接从溶酶体移动到内质网,还是首先必须穿过质膜,目前尚未确定。为了研究这个问题,在18℃下用[3H]胆固醇亚油酸酯标记的低密度脂蛋白(LDL)加载大鼠肝癌细胞的内吞途径,然后在37℃下进行追踪。积累的酯的水解持续数小时呈线性进行。几乎所有释放出的[3H]胆固醇都迅速移动到质膜,且没有明显的延迟。相比之下,释放出的[3H]胆固醇在内质网中的重新酯化显示出0.5 - 1小时的特征性延迟。这些数据与胆固醇从溶酶体直接转移到内质网不一致;相反,它们表明是通过质膜移动。此外,我们发现孕酮、丙咪嗪和3-β-[2-(二乙氨基)乙氧基]雄甾-5-烯-17-酮(U18666A)强烈抑制内质网中溶酶体胆固醇的重新酯化。然而,与之前的报道相反,它们并没有阻止[3H]胆固醇从溶酶体转移到细胞表面。因此,这些药物的作用位点不在溶酶体。我们反而认为,它们已知的阻止胆固醇从质膜移动到内质网的能力可以解释对溶酶体胆固醇酯化的抑制作用。这些发现与以下假设一致,即从溶酶体释放的胆固醇在前往内质网的途中穿过质膜,而不是直接到达那里。结果,摄取的胆固醇与位于质膜中的大部分细胞胆固醇一样受到相同的稳态调节。